BR0317600A - ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina - Google Patents

ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina

Info

Publication number
BR0317600A
BR0317600A BR0317600-2A BR0317600A BR0317600A BR 0317600 A BR0317600 A BR 0317600A BR 0317600 A BR0317600 A BR 0317600A BR 0317600 A BR0317600 A BR 0317600A
Authority
BR
Brazil
Prior art keywords
derivatives
receptor antagonists
integrin receptor
integrin
heteroarylalkanoic
Prior art date
Application number
BR0317600-2A
Other languages
English (en)
Inventor
Mark L Boys
Lori A Schretzman
Michael B Tollefson
Nizal S Chandrakumar
Ish K Khanna
Maria Nguyen
Victoria Downs
Scott B Mohler
Glen J Gesicki
Thomas D Penning
Barbara B Chen
Yaping Wang
Albert Khilevich
Bipinchandra N Desai
Yi Yu
John A Wendt
Heather Stenmark
Lisa Wu
Renee M Huff
Srinivasan R Nagarajan
Balekudru Devadas
Mark Russell
Dale P Spangler
Mihir D Parikh
Hwang-Fun Lu
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of BR0317600A publication Critical patent/BR0317600A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

"áCIDOS HETEROARILALCANóICOS COMO DERIVADOS DE ANTAGONISTAS DE RECEPTOR DE INTEGRINA". A presente invenção refere-se a composições farmacêuticas compreendendo compostos da Fórmula I, ou um seu sal farmaceuticamente aceitável, e métodos de inibição ou antagonização seletiva da <244>~ v~<225>~ 6~ e/ou da <244>~ v~<225>~ 5~ integrina sem significantemente inibir <244>~ v~<225>~6~ integrina.
BR0317600-2A 2002-12-20 2003-12-22 ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina BR0317600A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43546702P 2002-12-20 2002-12-20
PCT/US2003/040898 WO2004058254A1 (en) 2002-12-20 2003-12-22 Heteroarylalkanoic acids as integrin receptor antagonists

Publications (1)

Publication Number Publication Date
BR0317600A true BR0317600A (pt) 2005-11-29

Family

ID=32682246

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317600-2A BR0317600A (pt) 2002-12-20 2003-12-22 ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina

Country Status (8)

Country Link
US (1) US20050043344A1 (pt)
EP (1) EP1592421A1 (pt)
JP (1) JP2006518333A (pt)
AU (1) AU2003299807A1 (pt)
BR (1) BR0317600A (pt)
CA (1) CA2507699A1 (pt)
MX (1) MXPA05006727A (pt)
WO (1) WO2004058254A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070011458A (ko) 2004-04-08 2007-01-24 탈자진 인코포레이티드 키나제의 벤조트리아진 억제제
MX2007002208A (es) 2004-08-25 2007-05-08 Targegen Inc Compuestos hetrociclicos y metodos de uso.
US8133900B2 (en) 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en) 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
RU2597364C2 (ru) 2005-11-01 2016-09-10 Таргеджен, Инк. Би-арил-мета-пиримидиновые ингибиторы киназ
US20070155739A1 (en) * 2005-12-30 2007-07-05 Alantos Pharmaceuticals, Inc. Substituted bis-amide metalloprotease inhibitors
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
US9345739B2 (en) * 2007-11-08 2016-05-24 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
EP2544679B1 (en) 2010-03-12 2019-05-15 Omeros Corporation Pde10 inhibitors and related compositions and methods
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
CN102381961B (zh) * 2011-09-03 2014-01-15 四川大学 3-苯基戊二酸类化合物、其制备方法和用途
BR122019026750B1 (pt) * 2013-02-07 2022-03-03 Scifluor Life Sciences, Inc Compostos antagonistas de integrina fluorados
US8901144B2 (en) 2013-02-07 2014-12-02 Scifluor Life Sciences, Llc Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
SI3050878T1 (sl) 2013-09-24 2022-01-31 Fujifilm Corporation Nova dušik-vsebujoča spojina ali njena sol ali kovinski kompleks le-te
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
TWI736529B (zh) 2015-02-19 2021-08-21 美商賽氟洛生命科學公司 氟化之四氫啶基壬酸衍生物及其用途
RU2017134509A (ru) 2015-04-24 2019-04-04 Омерос Корпорейшн Ингибиторы pde10 и соответствующие композиции и способы
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
PL3538525T3 (pl) 2016-11-08 2022-09-12 Bristol-Myers Squibb Company 3-podstawione kwasy propionowe jako inhibitory integryny alfa v
BR112019012515A2 (pt) 2016-12-29 2019-11-19 Saint Louis University antagonistas de integrina
CN111433207B (zh) * 2017-11-07 2023-07-25 百时美施贵宝公司 作为αV整合素抑制剂的吡咯并吡嗪衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
ES2179318T3 (es) * 1996-03-29 2003-01-16 Searle & Co Derivados de acido cinamico y su uso como antagonistas de integrina.
PT889877E (pt) * 1996-03-29 2002-02-28 Searle & Co Derivados fenileno meta substituidos e sua utilizacao como antagonitas ou inibidores integrina alfa v beta3
DE19620041A1 (de) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
EP1049693A1 (en) * 1997-11-26 2000-11-08 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS
US7119098B2 (en) * 2000-06-15 2006-10-10 Pharmacia Corporation Heteroarylakanoic acids as intergrin receptor antagonists
US7556925B2 (en) * 2001-04-04 2009-07-07 University Of Rochester ανβ3 integrin-binding polypeptide monobodies and their use
US6750215B2 (en) * 2001-08-08 2004-06-15 Pharmacia & Upjohn, S.P.A. Substituted benzoxazines as integrin antagonists

Also Published As

Publication number Publication date
WO2004058254A1 (en) 2004-07-15
MXPA05006727A (es) 2005-09-08
EP1592421A1 (en) 2005-11-09
AU2003299807A1 (en) 2004-07-22
US20050043344A1 (en) 2005-02-24
JP2006518333A (ja) 2006-08-10
CA2507699A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
BR0317600A (pt) ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
WO2001096334A3 (en) Heteroarylalkanoic acids as integrin receptor antagonists
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
MY133473A (en) Haterocyclic glycyl beta-alanine derivatives.
ATE212978T1 (de) Para-substituierte phenylpropansäure derivate als integrin-antagonisten
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
GEP20094723B (en) Tetraazabenzo [e] azulene derivatives and analogs thereof
WO2004026248A3 (en) Octahydro-2-h-naphtho[1,2-f] indole-4-carboxamide derivatives as selective glucocorticoid receptor modulators
WO2001096307A3 (en) Cycloalkyl alkanoic acids as integrin receptor antagonists
IL172834A0 (en) Pyrimidine-,2,4-dione derivatives and pharmaceutical compositions containing the same
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
YU49700A (sh) 1,2,4,5-tetrahidro-benzo/d/azepini
TW200626158A (en) Naphthaline derivatives
BR0213452A (pt) Derivados de piperazina com atividade antagonista receptora de ccr1
MX2007006387A (es) Derivados de piridina 3-substituidos como antagonistas h3.
BR0213464A (pt) Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
WO2006077024A3 (en) 5-aminoindole derivatives
BRPI0407097A (pt) Antagonista do casr
BR0317487A (pt) O r-isÈmero de compostos de aminoácido beta como derivados de antagonistas de receptores de integrina
BR0210293A (pt) Uma preparação farmacêutica aquosa de cilostazol para utilização parenteral
HK1090543A1 (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
WO2001010860A3 (en) Quinazolinone and azaquinazolinone derivatives
ATE326451T1 (de) Chinazolin derivate und therapeutische verwendungen davon

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A E 7A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2073 DE 28/09/2010.